[Skip to Content]
[Skip to Content Landing]
Views 448
Citations 0
Special Communication
November 21, 2019

Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer

Author Affiliations
  • 1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
  • 2Abramson Cancer Center, Philadelphia, Pennsylvania
  • 3Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • 4Spectrum Health Cancer Center, Grand Rapids, Michigan
  • 5Memorial Sloan Kettering Cancer Center, New York, New York
  • 6University of Texas Southwestern Medical Center, Dallas
  • 7Department of Urology, SUNY Upstate Medical University, Syracuse, New York
  • 8Heart Failure Society of America, Rockville, Maryland
  • 9Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland
  • 10Oncology Center of Excellence, Food and Drug Administration, Silver Spring, Maryland
  • 11Fox Chase Cancer Center, Philadelphia, Pennsylvania
  • 12Dana-Farber Cancer Institute, Boston, Massachusetts
JAMA Oncol. Published online November 21, 2019. doi:https://doi.org/10.1001/jamaoncol.2019.4117
Abstract

Purpose  To harmonize the eligibility criteria and radiologic disease assessment definitions in clinical trials of adjuvant therapy for renal cell carcinoma (RCC).

Method  On November 28, 2017, US-based experts in RCC clinical trials, including medical oncologists, urologic oncologists, regulators, biostatisticians, radiologists, and patient advocates, convened at a public workshop to discuss eligibility for trial entry and radiologic criteria for assessing disease recurrence in adjuvant trials in RCC. Multiple virtual meetings were conducted to address the issues identified at the workshop.

Results  The key workshop conclusions for adjuvant RCC therapy clinical trials were as follows. First, patients with non–clear cell RCC could be routinely included, preferably in an independent cohort. Second, patients with T3-4, N+M0, and microscopic R1 RCC tumors may gain the greatest advantages from adjuvant therapy. Third, trials of agents not excreted by the kidney should not exclude patients with severe renal insufficiency. Fourth, therapy can begin 4 to 16 weeks after the surgical procedure. Fifth, patients undergoing radical or partial nephrectomy should be equally eligible. Sixth, patients with microscopically positive soft tissue or vascular margins without gross residual or radiologic disease may be included in trials. Seventh, all suspicious regional lymph nodes should be fully resected. Eighth, computed tomography should be performed within 4 weeks before trial enrollment; for patients with renal insufficiency who cannot undergo computed tomography with contrast, noncontrast chest computed tomography and magnetic resonance imaging of the abdomen and pelvis with gadolinium should be performed. Ninth, when feasible, biopsy should be undertaken to identify any malignant disease. Tenth, when biopsy is not feasible, a uniform approach should be used to evaluate indeterminate radiologic findings to identify what constitutes no evidence of disease at trial entry and what constitutes radiologic evidence of disease. Eleventh, a uniform approach for establishing the date of recurrence should be included in any trial design. Twelfth, patient perspectives on the use of placebo, conditions for unblinding, and research biopsies should be considered carefully during the conduct of an adjuvant trial.

Conclusions and Relevance  The discussions suggested that a uniform approach to eligibility criteria and radiologic disease assessment will lead to more consistently interpretable trial results in the adjuvant RCC therapy setting.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×